Document is current
Any future updates will be listed below
-
Authors
Escribano-Subias, Pilar
López, Raquel
Almenar, Luis
Lázaro, María
Forn, Ian
Torrent, Anna
Blanco, Isabel
Barberà, Joan Albert
,
Almenar, Luis
Dobaño, José Manuel Alvarez
Baloira, Adolfo
Barbado, Julia
Diaz, Pedro Bedate
Blanco, Isabel
Blanquer, David
Ruiz, Ana José Bustamante
Cadenas, Sergio
Casado, Ignacio
Chamorro, Carlos
Cifrian, José Manuel
Cremer, David
Delgado, Eva
Delgado, Juan Luis
Domingo, Juan Antonio
Escribano, Pilar
Arangüena, Luis García
Muñoz, Juan Pablo García
Iturbe, David
Lara, Antonio
Lázaro, María
Meseguer, Manuel López
López, Raquel
Madroñero, Ana
Marín, Adela
Ferragut, Lluis Molina
Escobar, Eduardo Moreno
Núñez, Ana
de Saracho y Bobo, Juan Ortiz
Peralta, Cilia Amparo
Peñate, Gregorio Pérez
Amigó, Javier Pomares
Rodriguez, Carlos
Roig, Vicente
Rueda, Ximo
Sala, Ernest
Simón, Rafaela Sánchez
-
Funding
Funding for this research was provided by:
Actelion Pharmaceuticals España S.L¸ (Actelion Pharmaceuticals España S.L¸)
- License Information
-
More Information
Article History
Received: 28 August 2019
Accepted: 22 May 2020
First Online: 2 June 2020
Ethics approval and consent to participate
: The protocol was approved by the independent ethics committee at Hospital universitario y politécnico la Fe (e-mail: , protocol reference number: ACT-MAC-2015-01) and all patients provided written informed consent before participation.
: Not applicable.
: PE has received has received consulting/speaker fees and advisory board from Actelion Pharmaceuticals España S.L; Bayer, GlaxoSmithKline and Merck Sharp & Dohme, her institution has received grant support from Actelion Pharmaceuticals España S.L; Bayer, GlaxoSmithKline and Ferrer, and has received honoraria for her collaboration in the PRACMA study. RL has received honoraria for her collaboration in the PRACMA study. ML has received honoraria for her collaboration in the PRACMA study, and educational and consulting honoraria from Actelion Pharmaceuticals España S.L. IA and AT were employees of Actelion Pharmaceuticals España S.L. IB has received honoraria for her collaboration in the PRACMA study. JAB has received honoraria for consultation or speaker fees from Actelion and Merck; research support through his institution from Actelion, Merck, GlaxoSmithKline and Ferrer; and has received honoraria for his collaboration in the PRACMA study.
